SCHEMBL13495394

SCHEMBL13495394

CCCCc1ccc2c(c1)C(=O)N(OC)C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SKP2 Q13309 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
CA2 P00918 2/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
CA1 P00915 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
NFKB1 P19838 2/20 0.37
RAB9A P51151 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12541824 0.82 CA2 (0.38) CA2ALDH1A1MEN1KMT2A
SCHEMBL13496137 0.79 KDM4E (0.38) CA2CA1MAPK1ALDH1A1HSD17B10
SCHEMBL8554990 0.77 PPARA (0.43) PPARGPPARARORARORCRORB
SCHEMBL24168448 0.74 MEN1 (0.59) SMN1; SMN2NPC1RAB9APOLBMAPK1
SCHEMBL23271913 0.71 SKP2 (0.44) SKP2FAAHMGLLCA2CA1
SCHEMBL12156954 0.71 ALDH1A1 (0.46) CA2CA1TDP1NPC1RAB9A
SCHEMBL13169414 0.71 CA1 (0.48) CA2PPARACA1POLBALDH1A1
SCHEMBL13495392 0.71 CA9 (0.46) CA2CA1NPC1RAB9AALDH1A1
SCHEMBL23271897 0.70 MAOA (0.50) SKP2CA2CA1SMN1; SMN2NPC1
SCHEMBL21578575 0.70 SKP2 (0.43) SKP2CA2CA1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC SKP2 1116/4885FAAH 1558/4885MGLL 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.